IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v13y2022i1d10.1038_s41467-022-31199-2.html
   My bibliography  Save this article

Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies

Author

Listed:
  • John Hilton

    (Ottawa Hospital Research Institute)

  • Karen Gelmon

    (BC Cancer - Vancouver Centre)

  • Philippe L. Bedard

    (University Health Network
    University of Toronto)

  • Dongsheng Tu

    (Canadian Cancer Trials Group)

  • Hong Xu

    (Molecular Oncology, BC Cancer Research Institute)

  • Anna V. Tinker

    (BC Cancer - Vancouver Centre)

  • Rachel Goodwin

    (Ottawa Hospital Research Institute)

  • Scott A. Laurie

    (Ottawa Hospital Research Institute)

  • Derek Jonker

    (Ottawa Hospital Research Institute)

  • Aaron R. Hansen

    (University Health Network
    University of Toronto)

  • Zachary W. Veitch

    (University Health Network
    University of Toronto)

  • Daniel J. Renouf

    (BC Cancer - Vancouver Centre)

  • Linda Hagerman

    (Canadian Cancer Trials Group)

  • Hongbo Lui

    (Canadian Cancer Trials Group)

  • Bingshu Chen

    (Canadian Cancer Trials Group)

  • Deb Kellar

    (Ottawa Hospital Research Institute)

  • Irene Li

    (University Health Network)

  • Sung-Eun Lee

    (BC Cancer - Vancouver Centre)

  • Takako Kono

    (Molecular Oncology, BC Cancer Research Institute)

  • Brian Y. C. Cheng

    (Molecular Oncology, BC Cancer Research Institute)

  • Damian Yap

    (Molecular Oncology, BC Cancer Research Institute)

  • Daniel Lai

    (Molecular Oncology, BC Cancer Research Institute)

  • Sean Beatty

    (Molecular Oncology, BC Cancer Research Institute)

  • John Soong

    (Senhwa Biosciences, Inc)

  • Kathleen I. Pritchard

    (Sunnybrook Health Sciences Centre)

  • Isabel Soria-Bretones

    (University Health Network)

  • Eric Chen

    (University Health Network)

  • Harriet Feilotter

    (Canadian Cancer Trials Group)

  • Moira Rushton

    (Canadian Cancer Trials Group)

  • Lesley Seymour

    (Canadian Cancer Trials Group)

  • Samuel Aparicio

    (Molecular Oncology, BC Cancer Research Institute
    Pathology and Laboratory Medicine, UBC)

  • David W. Cescon

    (University Health Network
    University of Toronto)

Abstract

CX-5461 is a G-quadruplex stabilizer that exhibits synthetic lethality in homologous recombination-deficient models. In this multicentre phase I trial in patients with solid tumors, 40 patients are treated across 10 dose levels (50–650 mg/m2) to determine the recommended phase II dose (primary outcome), and evaluate safety, tolerability, pharmacokinetics (secondary outcomes). Defective homologous recombination is explored as a predictive biomarker of response. CX-5461 is generally well tolerated, with a recommended phase II dose of 475 mg/m2 days 1, 8 and 15 every 4 weeks, and dose limiting phototoxicity. Responses are observed in 14% of patients, primarily in patients with defective homologous recombination. Reversion mutations in PALB2 and BRCA2 are detected on progression following initial response in germline carriers, confirming the underlying synthetic lethal mechanism. In vitro characterization of UV sensitization shows this toxicity is related to the CX-5461 chemotype, independent of G-quadruplex synthetic lethality. These results establish clinical proof-of-concept for this G-quadruplex stabilizer. Clinicaltrials.gov NCT02719977.

Suggested Citation

  • John Hilton & Karen Gelmon & Philippe L. Bedard & Dongsheng Tu & Hong Xu & Anna V. Tinker & Rachel Goodwin & Scott A. Laurie & Derek Jonker & Aaron R. Hansen & Zachary W. Veitch & Daniel J. Renouf & L, 2022. "Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies," Nature Communications, Nature, vol. 13(1), pages 1-12, December.
    • Handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-31199-2
    DOI: 10.1038/s41467-022-31199-2
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-022-31199-2
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-022-31199-2?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Min Pan & William C. Wright & Richard H. Chapple & Asif Zubair & Manbir Sandhu & Jake E. Batchelder & Brandt C. Huddle & Jonathan Low & Kaley B. Blankenship & Yingzhe Wang & Brittney Gordon & Payton A, 2021. "The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma," Nature Communications, Nature, vol. 12(1), pages 1-20, December.
    2. Stacey L. Edwards & Rachel Brough & Christopher J. Lord & Rachael Natrajan & Radost Vatcheva & Douglas A. Levine & Jeff Boyd & Jorge S. Reis-Filho & Alan Ashworth, 2008. "Resistance to therapy caused by intragenic deletion in BRCA2," Nature, Nature, vol. 451(7182), pages 1111-1115, February.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Robert Appleby & Luay Joudeh & Katie Cobbett & Luca Pellegrini, 2023. "Structural basis for stabilisation of the RAD51 nucleoprotein filament by BRCA2," Nature Communications, Nature, vol. 14(1), pages 1-12, December.
    2. Yonina R. Murciano-Goroff & Alison M. Schram & Ezra Y. Rosen & Helen Won & Yixiao Gong & Anne Marie Noronha & Yelena Y. Janjigian & Zsofia K. Stadler & Jason C. Chang & Soo-Ryum Yang & Diana Mandelker, 2022. "Reversion mutations in germline BRCA1/2-mutant tumors reveal a BRCA-mediated phenotype in non-canonical histologies," Nature Communications, Nature, vol. 13(1), pages 1-10, December.
    3. Melvin Pan & Christiane Zorbas & Maki Sugaya & Kensuke Ishiguro & Miki Kato & Miyuki Nishida & Hai-Feng Zhang & Marco M. Candeias & Akimitsu Okamoto & Takamasa Ishikawa & Tomoyoshi Soga & Hiroyuki Abu, 2022. "Glutamine deficiency in solid tumor cells confers resistance to ribosomal RNA synthesis inhibitors," Nature Communications, Nature, vol. 13(1), pages 1-14, December.
    4. Hyeong-Min Lee & William C. Wright & Min Pan & Jonathan Low & Duane Currier & Jie Fang & Shivendra Singh & Stephanie Nance & Ian Delahunty & Yuna Kim & Richard H. Chapple & Yinwen Zhang & Xueying Liu , 2023. "A CRISPR-drug perturbational map for identifying compounds to combine with commonly used chemotherapeutics," Nature Communications, Nature, vol. 14(1), pages 1-18, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-31199-2. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.